Latest news with #CABOMETYX
Yahoo
22-05-2025
- Business
- Yahoo
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
- Presentations to be webcast on - ALAMEDA, Calif., May 22, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City. To access the webcast links, log onto and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks. View source version on Contacts Investors Contact: Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@ Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@ Sign in to access your portfolio
Yahoo
22-05-2025
- Business
- Yahoo
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
- Presentations to be webcast on - ALAMEDA, Calif., May 22, 2025--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May and June: TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Exelixis is scheduled to present virtually at 2:30 p.m. ET / 11:30 a.m. PT on Tuesday, May 27. William Blair 45th Annual Growth Stock Conference: Exelixis is scheduled to present at 11:00 a.m. ET / 10:00 a.m. CT / 8:00 a.m. PT on Tuesday, June 3 in Chicago. Jefferies Global Healthcare Conference 2025: Exelixis is scheduled to present at 7:35 a.m. ET / 4:35 a.m. PT on Wednesday, June 4 in New York City. To access the webcast links, log onto and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks. View source version on Contacts Investors Contact: Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 vshirvanian@ Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 hal@ Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other firms blowing up by double digits today. Ten individual stocks soared by double digits on Wednesday, outperforming a lackluster performance among Wall Street's indices, thanks to the 90-day truce between the US and China that continued to boost investor confidence. In contrast, Wall Street's indices were mixed, with the tech-heavy Nasdaq growing 0.72 percent, followed by the S&P 500, up 0.10 percent. The Dow Jones declined by 0.21 percent. In this article, we name Wednesday's 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. Exelixis soared by 20.84 percent on Wednesday to finish at $44.65 each following a strong earnings performance in the first three months, coupled with a more optimistic outlook for the rest of the year. In its latest earnings release, Exelixis, Inc. (NASDAQ:EXEL) said net income expanded by 332 percent to $160 million from $37 million in the same period last year. Revenues, on the other hand, grew by 30 percent to $555 million from $425 million year-on-year, primarily due to an increase in sales volume and an increase in average net selling price. 'Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX demand, new patient starts, and revenues,' said President and CEO Michael Morrissey. Based on the strong figures, the company has raised its growth outlook for net product revenues and total revenues, both by $100 million for the full year. Overall, EXEL ranks 1st on our list of firms blowing up by double digits today. While we acknowledge the potential of EXEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EXEL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday
We recently published a list of . In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other firms blowing up by double digits today. Ten individual stocks soared by double digits on Wednesday, outperforming a lackluster performance among Wall Street's indices, thanks to the 90-day truce between the US and China that continued to boost investor confidence. In contrast, Wall Street's indices were mixed, with the tech-heavy Nasdaq growing 0.72 percent, followed by the S&P 500, up 0.10 percent. The Dow Jones declined by 0.21 percent. In this article, we name Wednesday's 10 best-performing stocks and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. Exelixis soared by 20.84 percent on Wednesday to finish at $44.65 each following a strong earnings performance in the first three months, coupled with a more optimistic outlook for the rest of the year. In its latest earnings release, Exelixis, Inc. (NASDAQ:EXEL) said net income expanded by 332 percent to $160 million from $37 million in the same period last year. Revenues, on the other hand, grew by 30 percent to $555 million from $425 million year-on-year, primarily due to an increase in sales volume and an increase in average net selling price. 'Exelixis delivered outstanding financial performance in the first quarter of 2025, driven by accelerating growth in CABOMETYX demand, new patient starts, and revenues,' said President and CEO Michael Morrissey. Based on the strong figures, the company has raised its growth outlook for net product revenues and total revenues, both by $100 million for the full year. Overall, EXEL ranks 1st on our list of firms blowing up by double digits today. While we acknowledge the potential of EXEL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EXEL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
Exelixis [NasdaqGS:EXEL] Sees US$555 Million Revenue With Earnings Up Sharply
Exelixis recently announced its impressive first-quarter earnings for 2025, with revenue and net income showing substantial growth. This financial performance, coupled with the FDA approval of CABOMETYX for new indications, likely contributed to the company's 12.65% share price increase over the last quarter. The company's share repurchase program announcement also adds potential upward pressure, reflecting confidence in its future prospects. Given the broader market's 12% annual increase and recent 4% rise, Exelixis's price movement aligns well with overall market trends, with its strong earnings and strategic product advancements adding supportive momentum. Be aware that Exelixis is showing 1 possible red flag in our investment analysis. This technology could replace computers: discover the 22 stocks are working to make quantum computing a reality. Exelixis's recent FDA approval and strong earnings performance have set a bullish investors' narrative, aligning with analysts' positive projections for revenue and earnings growth. Over the past three years, the company's total shareholder return was very large at 78.59%, indicating strong historical performance. In comparison, over the past year, Exelixis's stock outperformed the US Market, which returned 11.5%. This past performance suggests resiliency and an ability to drive growth, factors that may further encourage investor confidence as the company expands its cabozantinib indications and accelerates its Phase I pipeline development. The approval and increased indications of CABOMETYX, combined with potential revenue growth driven by new oncology franchises, could significantly enhance Exelixis's revenue and earnings projections. Analysts forecast a revenue increase of 9.7% annually, with earnings expected to reach US$943 million by 2028. These developments support the recent strategic decisions, such as the share repurchase program, which may positively impact earnings per share by reducing outstanding shares. The current share price of US$36.86 shows a marginal discount of approximately 3.1% to analysts' consensus price target of US$38.05, reflecting market confidence in Exelixis being fairly valued at present. These projections underline the company's ambition to solidify its market position while highlighting underlying business challenges such as rising costs and competitive pressures. Assess Exelixis' future earnings estimates with our detailed growth reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:EXEL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
